Milestone Pharmaceuticals

MIST · NASDAQ

$0.6482−$0.0545 (−7.76%)TodayMarket closed · Oct 23, 7:59 PM ET

Prev close $0.7027

About MIST

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 38 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Employees: 38
Headquarters: MONTREAL, Quebec
Listed: May 9, 2019
Sector: Health Care
Industry: Pharmaceuticals
Website: milestonepharma.com

Leadership

Milestone Pharmaceuticals executives
Name	Title	Since	Age
Robert Wills	—	—	71
Joseph Oliveto	—	2017	58
Amit Hasija	—	—	52
Jeffrey Nelson	—	—	44
David Sandoval	—	—	47
David Bharucha	—	—	63
Lorenz Muller	—	—	61
Stuart Duty	—	—	60
Seth Fischer	—	—	69
Lisa Giles	—	—	66
Joseph Papa	—	—	69
Andrew Saik	—	—	55
Michael Tomsicek	—	—	59

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Milestone Pharmaceuticals suppliers and customers
Company	Relationship	Country	Correlation
Jixing Pharmaceutical Technology (Shanghai) Co. Ltd.	Customer	CN	—
@NA	Supplier and customer	—	—

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.